Search Our Scientific Publications & Authors

Front Med (Lausanne) 2022 6;9:864972. Epub 2022 May 6.

Virology Unit, Institut Pasteur du Cambodge, Pasteur Network, Phnom Penh, Cambodia.

Introduction: Accurate and sensitive measurement of antibodies is critical to assess the prevalence of infection, especially asymptomatic infection, and to analyze the immune response to vaccination during outbreaks and pandemics. A broad variety of commercial and in-house serological assays are available to cater to different laboratory requirements; however direct comparison is necessary to understand utility.

Materials And Methods: We investigate the performance of six serological methods against SARS-CoV-2 to determine the antibody profile of 250 serum samples, including 234 RT-PCR-confirmed SARS-CoV-2 cases, the majority with asymptomatic presentation (87. Read More

Epidemiol Mikrobiol Imunol 2022 ;71(1):3-8

Objectives: To map the prevalence of SARS-CoV-2 antibodies in the staff of the Thomayer University Hospital in Prague following the first wave of COVID-19. The main reason was the large number of COVID-19 patients admitted to the Thomayer University Hospital with confirmed SARS-CoV-2 infection.

Material And Methods: A volunteer study based on a questionnaire survey and determination of total antibodies (ECLIA, Roche) and individual classes of immunoglobulins (ELISA IgG and IgA, Euroimmun). Read More

J Clin Virol Plus 2021 Sep 18;1(3):100038. Epub 2021 Aug 18.

Institute for Medical Microbiology and Virology, University Hospital and Medical Faculty, University of Leipzig Germany.

SARS-CoV-2-specific IgM antibodies wane during the first three months after infection and IgG antibody levels decline. This may limit the ability of antibody tests to identify previous SARS-CoV-2 infection at later time points. To examine if the diagnostic sensitivity of antibody tests falls off, we compared the sensitivity of two nucleoprotein-based antibody tests, the Roche Elecsis II Anti-SARS-CoV-2 and the Abbott SARS-CoV-2 IgG assay and three glycoprotein-based tests, the Abbott SARS-CoV-2 IgG II Quant, Siemens Atellica IM COV2T and Euroimmun SARS-CoV-2 assay with 53 sera obtained 6 months after SARS-CoV-2 infection. Read More

Clin Chem Lab Med 2022 04 3;60(5):655-661. Epub 2022 Feb 3.

IFCC Task Force on COVID-19, Milan, Italy.

Objectives: Among the diagnostic tests that have recently become commercially available for diagnosing coronavirus disease 2019 (COVID-19), the fully-automated Roche Elecsys severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen electrochemiluminescence immunoassay (ECLIA) is one of the most widespread for its adaptability within a system of laboratory automation, rapidity and high-throughput. This article is aimed to provide the results of the first pooled analysis of its accuracy for diagnosing SARS-CoV-2 infections.

Content: We carried out an electronic search in Scopus and Medline, without language or date restrictions (i. Read More

Pract Lab Med 2022 Mar 15;29:e00265. Epub 2022 Jan 15.

Section of Clinical Biochemistry, University of Verona, Verona, Italy.

Objective: We assessed the clinical performance of novel Roche Elecsys SARS-CoV-2 Antigen fully automated electrochemiluminescence immunoassay (ECLIA).

Design And Methods: We tested 160 subjects, 110 (68.8%), with positive molecular test for SARS-CoV-2 infection in nasopharyngeal samples, with Altona Diagnostics RealStar SARS-CoV-2 RT-PCR Kit and Roche Elecsys SARS-CoV-2 Antigen. Read More